RICARDO KATSUYA TOMA

(Fonte: Lattes)
Índice h a partir de 2011
4
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 27
  • article 1 Citação(ões) na Scopus
    Hepatitis C in Children and Adolescents of a Brazilian Tertiary Center Identifying Patients Eligible for Direct-Acting Antivirals
    (2020) HIRSCH, Camila Bellettini; PEREIRA, Maria Fernanda Badue; BENEVIDES, Gabriel Nuncio; BERNARDES, Tamires Miranda; PALANDRI, Giovanna Gavros; BASTOS, Karina Lucio de Medeiros; TOMA, Ricardo Katsuya; AZEVEDO, Ramiro Anthero de; MARQUES, Heloisa Helena de Sousa
    We evaluated 113 pediatric patients with chronic hepatitis C from 2009 to 2019 at a Brazilian tertiary center. Seventy patients received pegylated-interferon treatment. The sustained virologic response was 61.4%, and 92.8% reported side effects. Currently, we are following 39 patients with chronic hepatitis C, 24 of whom are eligible for treatment with direct-acting antivirals according to Brazilian recommendations.
  • conferenceObject
    Activated PI3K-Delta Syndrome (APDS): A Monogenic Cause of VEO-IBD That Impacts on Treatment
    (2019) LINDOSO, Livia; DEBONI, Mariana; DORNA, Mayra Barros; CASTRO, Ana Paula Moschione; PASTORINO, Antonio Carlos; TOMA, Ricardo
  • conferenceObject
    Changes on Gut Microbiota after Laparoscopic Sleeve Gastrectomy in Adolescence: Case Reports
    (2019) RACHID, L.; COMINATO, L.; FRANCO, R. R.; V, R. Cortez; MOREIRA, L. N.; FRASCINO, A.; TADDEI, C. R.; STEINMETZ, L.; MANNA, T. Della; VELHOTE, M. C. P.; FILHO, H. C. M.; TOMA, R. K.; DAMIANI, D.
  • bookPart
    Doença celíaca
    (2022) BIBAS, Mariana Deboni; TOMA, Ricardo Katsuya
  • bookPart
    Diarreia crônica
    (2022) TOMA, Ricardo Katsuya; BIBAS, Mariana Deboni
  • bookPart
    Manifestações gastrointestinais e do sistema nervoso na COVID-19
    (2021) TOMA, Ricardo Katsuya; PAZ, José Albino da; LUGLIO, Michele
  • conferenceObject
    Phenotypic and Genotypic Characterization of VEOIBD: Experience From a Single-Centre in Brazil
    (2019) VIANNA, Marina Santana; ANTUNES, Karina de Almeida Vieira; SANTOS, Paloma Estefanne Barbosa dos; SEOANE, Marcela S.; LINDOSO, Livia; TOMA, Ricardo; DEBONI, Mariana
  • bookPart
    Alergia alimentar não IgE mediada
    (2021) BENEVIDES, Gabriel Nuncio; TOMA, Ricardo Katsuya
  • article 3 Citação(ões) na Scopus
    Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations?
    (2017) VALOES, Clarissa C. M.; NOVAK, Glaucia V.; BRUNELLI, Juliana B.; KOZU, Katia T.; TOMA, Ricardo K.; SILVA, Clovis A.
    Objective: To assess esophageal involvement (EI) in juvenile localized scleroderma (JLS) population and the possible association between this gastrointestinal manifestation and demographic data, clinical features, laboratory exams, treatments and outcomes. Methods: For a period of 30 years, 5881 patients with rheumatic diseases were followed in our Pediatric Rheumatology Division. EI was defined by the presence of symptoms (solid/liquid dysphagia, heartburn, esophageal regurgitation, nausea/vomiting and epigastralgia) and confirmed by at least one EI exam abnormality: barium contrast radiography, upper gastrointestinal endoscopy and 24-hour esophageal pH-monitoring. Results: JLS was observed in 56/5881 patients (0.9%), mainly linear morphea subtype. EI was observed in 23/56(41%) of JLS patients. Eight(35%) of 23 EI patients with JLS were symptomatic and presented heartburn(5/8), solid and liquid dysphagia(3/8), nausea and epigastralgia(1/8). The frequency of any cumulative extracutaneous manifestations (calcinosis, arthritis/arthralgia, central nervous system, interstitial pneumonitis, mesangial nephritis and/or arrhythmia) was significantly higher in JLS patients with EI compared to those without this complication (56% vs. 24%, p = 0.024). No differences were evidenced in demographic data, JLS subtypes and in each extracutaneous manifestation in both groups (p > 0.05). The frequency of methotrexate use was significantly higher in JLS patients with EI compared to those without (52% vs. 12%, p = 0.002). Autoantibody profile (antinuclear antibodies, antiSCL-70, rheumatoid factor, anticentromere, anti-cardiolipin, anti-Ro/SSA and anti-La/SSB) was similar in both groups (p > 0.05). Conclusions: Our study demonstrated that EI was frequently observed in JLS patients, mainly in asymptomatic patients with linear subtype. EI occurred in JLS patients with other extra cutaneous manifestations and required methotrexate therapy. (C) 2016 Published by Elsevier Editora Ltda.
  • article 5 Citação(ões) na Scopus
    Gastrointestinal manifestations are associated with severe pediatric COVID-19: A study in tertiary hospital
    (2021) PAULA, Camila Sanson Yoshino de; PALANDRI, Giovanna Gavros; FONSECA, Taiane Siraisi; VENDRAMINI, Thais Cristina Annibale; FARHAT, Sylvia Costa Lima; PEREIRA, Maria Fernanda Badue; LITVINOV, Nadia; TOMA, Ricardo Katsuya; SA, Fernanda Viveiros Moreira de; RODRIGUES, Katharina Reichmann; SCHVARTSMAN, Claudio; FORSAIT, Silvana; SAKITA, Neusa Keico; KANUNFRE, Kelly Aparecida; ROCHA, Mussya Cisotto; SANTOS, Emilly Henrique dos; OKAY, Thelma Suely; PINHO, Joao Renato Rebello; CARVALHO, Werther Brunow de; CARNEIRO-SAMPAIO, Magda; SILVA, Clovis Artur Almeida; MARQUES, Heloisa Helena de Sousa; EISENCRAFT, Adriana Pasmanik; ROSSI JUNIOR, Alfio; DELGADO, Artur Figueiredo; LEAL, Gabriela Nunes; FRAMIL, Juliana Valeria de Souza; GIBELLI, Maria Augusta Bento Cicaroni; JORGE, Patricia Palmeira Daenekas